Search Within

Kurt Bantilan

Formats
  1. Meeting Abstract (13)
  2. Journal Article (9)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. Hematologic Malignancies, Division of (25)
  4. Lymphoma (25)
  5. Executive Committee, Center for Hematologic Malignancies (8)
  6. Survivorship Research (8)

More Groups

People
  1. Andrew Zelenetz (20)
  2. Alison Moskowitz (10)
  3. Maria Palomba (9)
  4. Anita Kumar (8)
  5. Matthew Matasar (8)
  6. Paul Hamlin (7)

More People

Years
  1. 2024 (2)
  2. 2023 (4)
  3. 2022 (4)
  4. 2021 (1)
  5. 2020 (3)
  6. 2019 (4)

More Years

Publications
  1. Blood (13)
  2. Leukemia and Lymphoma (4)
  3. Blood Advances (3)
  4. British Journal of Haematology (1)
  5. Clinical Lymphoma, Myeloma and Leukemia (1)
  6. Hematological Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Taylor & Francis Group (4)
  3. Elsevier Inc. (1)
  4. John Wiley & Sons (1)
  5. Public Library of Science (1)
  6. Society of Nuclear Medicine (1)

More Publishers

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma
    Correspondence

    Gurumurthi, A.; Bantilan, K. S.; Hamlin, P. A.; Kumar, A.; Matasar, M.; Zhu, M.; Joseph, A.; Castro, A.; Biggar, E.; Salles, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
    Journal Article

    Bantilan, K. S.; Smith, A. N.; Maurer, M. J.; Teruya-Feldstein, J.; Matasar, M. J.; Moskowitz, A. J.; Straus, D. J.; Noy, A.; Palomba, M. L.; Horwitz, S. M.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Predicted functional consequences of TP53 alterations and prognosis in TP53-mutated mantle cell lymphoma
    Meeting Abstract

    Uppal, M.; Joffe, E.; Bantilan, K. S.; Salles, G.; Soumerai, J.; Zelenetz, A. D.; Kumar, A.
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluation of the m7-FLIPI in patients with follicular lymphoma: FOXO1 mutational status may be a predictive marker of early progression and long-term outcome
    Meeting Abstract

    Bantilan, K. S.; Zelenetz, A. D.
    Blood (2023)

    Fulltext@MSK | Save
  • Prognostic value of (18)F-FDG PET/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen
    Journal Article

    Michaud, L.; Bantilan, K.; Mauguen, A.; Moskowitz, C. H.; Zelenetz, A. D.; Schöder, H.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: Identifying risk factors to help guide treatment selection
    Journal Article

    Bantilan, K. S.; Kay, N. E.; Parikh, S. A.; Rabe, K. G.; Call, T. G.; Leis, J. F.; Ding, W.; Slager, S. L.; Soumerai, J. D.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Long-term outcome of patients with follicular lymphoma is not fundamentally affected by KMT2D, EZH2, and CREBBP mutational status
    Meeting Abstract

    Bantilan, K. S.; Rutherford, K.; McCarter, J.; Farnoud, N.; Arango-Ossa, J. E.; Papaemmanuil, E.; Zelenetz, A. D.
    Blood (2022)

    Fulltext@MSK | Save
  • Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
    Research Letter

    Soumerai, J. D.; Rosenthal, A.; Harkins, S.; Duffy, J.; Mecca, C.; Wang, Y.; Grewal, R. K.; El-Jawahri, A. R.; Liu, H.; Menard, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma
    Journal Article

    Fischer, T.; Ni, A.; Bantilan, K. S.; Soumerai, J. D.; Alperovich, A.; Batlevi, C.; Younes, A.; Zelenetz, A. D.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
    Research Letter

    Thompson, M. C.; Harrup, R. A.; Coombs, C. C.; Roeker, L. E.; Pu, J. J.; Choi, M. Y.; Barr, P. M.; Allan, J. N.; Šimkovič, M.; Leslie, L.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save